ATE464390T1 - Verfahren zur herstellung von insulinverbindungen - Google Patents

Verfahren zur herstellung von insulinverbindungen

Info

Publication number
ATE464390T1
ATE464390T1 AT02779247T AT02779247T ATE464390T1 AT E464390 T1 ATE464390 T1 AT E464390T1 AT 02779247 T AT02779247 T AT 02779247T AT 02779247 T AT02779247 T AT 02779247T AT E464390 T1 ATE464390 T1 AT E464390T1
Authority
AT
Austria
Prior art keywords
insulin compounds
producing insulin
compounds
insulin
ester
Prior art date
Application number
AT02779247T
Other languages
English (en)
Inventor
Are Bogsnes
Ingun Christiansen
Per Balschmidt
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Application granted granted Critical
Publication of ATE464390T1 publication Critical patent/ATE464390T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT02779247T 2001-11-19 2002-11-15 Verfahren zur herstellung von insulinverbindungen ATE464390T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200101716 2001-11-19
PCT/DK2002/000765 WO2003044210A2 (en) 2001-11-19 2002-11-15 Process for preparing insulin compounds

Publications (1)

Publication Number Publication Date
ATE464390T1 true ATE464390T1 (de) 2010-04-15

Family

ID=8160841

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02779247T ATE464390T1 (de) 2001-11-19 2002-11-15 Verfahren zur herstellung von insulinverbindungen

Country Status (15)

Country Link
EP (1) EP1448786B1 (de)
JP (1) JP4404631B2 (de)
KR (1) KR100925381B1 (de)
CN (1) CN100424179C (de)
AT (1) ATE464390T1 (de)
AU (1) AU2002342597A1 (de)
BR (1) BR0213583A (de)
CA (1) CA2464616C (de)
DE (1) DE60236014D1 (de)
ES (1) ES2344448T3 (de)
HU (1) HU228934B1 (de)
IL (2) IL161358A0 (de)
PL (1) PL210437B1 (de)
RU (1) RU2376379C2 (de)
WO (1) WO2003044210A2 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102006031955A1 (de) * 2006-07-11 2008-01-17 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung von Insulinanaloga mit dibasischem B-Kettenende
DE102006031962A1 (de) * 2006-07-11 2008-01-17 Sanofi-Aventis Deutschland Gmbh Amidiertes Insulin Glargin
TW200902708A (en) * 2007-04-23 2009-01-16 Wyeth Corp Methods of protein production using anti-senescence compounds
CA2740685C (en) 2008-10-17 2018-09-11 Sanofi-Aventis Deutschland Gmbh Combination of an insulin and a glp-1 agonist
MX346473B (es) * 2009-08-11 2017-03-22 Biocon Ltd Procesos cromatograficos y compuestos purificados de los mismos.
AU2010317995B2 (en) 2009-11-13 2014-04-17 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a GLP-1 agonist, an insulin, and methionine
JP5973918B2 (ja) 2009-11-13 2016-08-23 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Ｇｌｐ−１アゴニスト及びメチオニンを含む薬学的組成物
JP6199186B2 (ja) 2010-08-30 2017-09-20 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング ２型糖尿病の治療用の医薬の製造のためのａｖｅ００１０の使用
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
RU2650616C2 (ru) 2011-08-29 2018-04-16 Санофи-Авентис Дойчланд Гмбх Фармацевтическая комбинация для применения при гликемическом контроле у пациентов с сахарным диабетом 2 типа
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
CN102703552B (zh) * 2012-05-15 2014-10-29 山东阿华生物药业有限公司 重组人胰岛素的制备方法及其产品
CN102816819B (zh) * 2012-08-13 2014-10-29 山东阿华生物药业有限公司 提高人胰岛素前体融合蛋白酶切转换成b30缺苏氨酸人胰岛素产率的方法
CN103305581B (zh) * 2013-07-04 2015-05-27 珠海联邦制药股份有限公司 一种重组人胰岛素的制备方法
US10611813B2 (en) * 2013-12-23 2020-04-07 Biocon Research Limited Method of production of human insulin methyl ester
HRP20230470T1 (hr) 2014-12-12 2023-07-21 Sanofi-Aventis Deutschland Gmbh Formulacija fiksnog omjera inzulin glargin/liksisenatid
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
KR20170036643A (ko) * 2015-09-24 2017-04-03 한미약품 주식회사 인슐린의 제조 방법

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE50892B1 (en) 1980-02-11 1986-08-06 Novo Industri As Process for preparing insulin esters
WO1983001074A1 (en) 1981-09-15 1983-03-31 Andresen, Finn, Hede Enzymatic preparation of human insulin or b-30 esters thereof
WO1983000504A1 (en) 1981-08-10 1983-02-17 Andresen, Finn, Hede Enzymatic preparation of human insulin
DK149824C (da) 1982-01-22 1987-03-16 Carlsberg Biotechnology Ltd Fremgangsmaade til enzymatisk udskiftning af b-30 aminosyrer i insuliner
EP0087238A1 (de) 1982-02-08 1983-08-31 Biogen N.V. Methode zur Herstellung von menschlichem Insulin aus nichtmenschlichem Insulin-
DK347086D0 (da) 1986-07-21 1986-07-21 Novo Industri As Novel peptides
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
IL84110A (en) * 1986-10-14 1992-11-15 Lilly Co Eli Process for transforming a human insulin precursor to a human insulin
CA1339416C (en) 1987-02-25 1997-09-02 Liselotte Langkjaer Insulin derivatives
US6011007A (en) 1993-09-17 2000-01-04 Novo Nordisk A/S Acylated insulin
RO112873B1 (ro) 1993-09-17 1998-01-30 Novo Nordisk As Derivati de insulina
HUP0203475A3 (en) 1999-12-29 2005-11-28 Novo Nordisk As Method for making insulin precursors and insulin precursor analogs
WO2001049870A1 (en) 1999-12-29 2001-07-12 Novo Nordisk A/S Method for making insulin precursors and insulin precursor analogues having improved fermentation yield in yeast
ATE381573T1 (de) 2000-04-14 2008-01-15 Univ Maryland Biotech Inst Verbesserte thermostabilität und temperaturresistenz von proteinen
US20040198960A1 (en) 2001-03-29 2004-10-07 Janoff Edward N Human monoclonal antibodies against capsular polysaccharides of streptococcus pneumoniae

Also Published As

Publication number Publication date
DE60236014D1 (de) 2010-05-27
HUP0500037A3 (en) 2010-01-28
CA2464616A1 (en) 2003-05-30
CN100424179C (zh) 2008-10-08
KR20050044855A (ko) 2005-05-13
RU2376379C2 (ru) 2009-12-20
CN1589328A (zh) 2005-03-02
WO2003044210A3 (en) 2004-03-25
WO2003044210A2 (en) 2003-05-30
JP4404631B2 (ja) 2010-01-27
ES2344448T3 (es) 2010-08-27
AU2002342597A1 (en) 2003-06-10
IL161358A (en) 2011-05-31
AU2002342597A8 (en) 2003-06-10
CA2464616C (en) 2012-07-24
KR100925381B1 (ko) 2009-11-09
RU2004118503A (ru) 2005-06-10
EP1448786B1 (de) 2010-04-14
HUP0500037A2 (hu) 2005-03-29
IL161358A0 (en) 2004-09-27
EP1448786A2 (de) 2004-08-25
BR0213583A (pt) 2004-08-24
PL369447A1 (en) 2005-04-18
PL210437B1 (pl) 2012-01-31
HU228934B1 (hu) 2013-06-28
JP2005509687A (ja) 2005-04-14

Similar Documents

Publication Publication Date Title
ATE464390T1 (de) Verfahren zur herstellung von insulinverbindungen
ATE461270T1 (de) Verfahren zur herstellung von l-aminosäuren
DE60028777D1 (de) Verfahren zur herstellung von 1,3-propanediol durch einen rekombinanten micro-organismus in abwesenheit von coenzym b12
DE602005024809D1 (de) Verfahren zur herstellung von gabapentin
DE60315014D1 (de) Verfahren zur herstellung sequenzspezifischer proteasen durch gezielte evolution
ATE271533T1 (de) Verfahren zur herstellung von alkincarbonsäuren durch oxidation von alkinalkoholen
ATE458066T1 (de) Verfahren zur herstellung von substituierten carbonsäureestern mittels enzymatischer hydrolyse
DE50311645D1 (de) Verfahren zur enzymatischen Herstellung enantiomerenangereicherter Beta-Aminosäuren
DE50304116D1 (de) Verfahren zur enzymatischen Herstellung enantiomerenangereicherter beta-Aminosäuren
DE50109832D1 (de) Verfahren zur herstellung von essigsäure
ATE285393T1 (de) Verfahren zur herstellung von (r)-2-brom-3- phenylpropionsäure
ATE301637T1 (de) Verfahren zur herstellung von n-geschützten azetidin-2-carbonsäuren
DE50208458D1 (de) Verfahren zur Herstellung von Lithiumamid
ATA2852003A (de) Verfahren zur herstellung chiraler alpha-hydroxycarbonsäuren durch enzymatische hydrolyse von chiralen cyanhydrinen
ATE223901T1 (de) Verfahren zur herstellung von 5,7 dichlor-4- hydroxychinolin
ATE423215T1 (de) Verfahren zur herstellung von lysosphingolipiden
DE60034699D1 (de) Verfahren zur herstellung von fumagillin
ATE334963T1 (de) Verfahren zur herstellung von 4 methylamino 4 phenylpiperidin
ATE297478T1 (de) Verfahren zur herstellung von orthocarbonsäuretrialkylestern
ATE296895T1 (de) Verfahren zur herstellung von c4-c12-fettsäuren
ATE321030T1 (de) Verfahren zur herstellung von phenylen-bis- benzimidazol-tetrasulfonsäure-dinatriumsalz
ATE298762T1 (de) Verfahren zur herstellung von desclarithromycin, sowie zwischenprodukte
ATE212642T1 (de) Verfahren zur herstellung von aspartyl- cyclohexylalaninamid
DE602005014381D1 (de) Verfahren zur herstellung von 10,11-dihydro-10-hydroxy-5-h-dibenzäb,füazepin-5-carbonsäureamid
ATE155819T1 (de) Verfahren zur herstellung von optisch aktivem vinylglycin in freier oder geschützter form über eine enzymatische, enantioselektive hydrolyse

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties